Results: Program Guide – ASCO Meeting Program GuideIn Phase 1, four patients were enrolled into each of the three cohorts at 10 μg/dose, 50 μg/dose and 100 μg/dose IMU-201 with no DLTs observed. In the 10 μg/dose cohort, one patient achieved CR and one patient SD; in the 50 μg/dose cohort, four patients achieved SD; and in the 100 μg/dose cohort, one patient achieved PR and two patients achieved SD. Within the 100 μg/dose cohort, one patient experienced an immune related pneumonitis after two IMU-201 administrations and discontinued from study treatment.Conclusions:IMU-201 had no observed DLT and demonstrated preliminary signs of efficacy. The study will therefore move into Phase 1b with IMU-201 being assessed in combination with atezolizumab. Clinical trial information: NCT04432207.
Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT, page-2
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $548.9M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.8¢ | 7.5¢ | $1.261M | 16.55M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 2015361 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 590270 | 2 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
-0.001 ( 1.32 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.8¢ | 7.5¢ | 8715272 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| IMU (ASX) Chart |